Mika Kontro

Also affiliated with Helsinki University Hospital, Finnish Cancer Registry, Institute for Molecular Medicine Finland, Cancer Society of Finland

MedicineBiochemistry, Genetics and Molecular BiologyComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes”.

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

American Journal of Hematology(2023)10.1002/ajh.27161

N/A

0DataRank · unranked

48 citations

Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl +22 more

Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemia

npj Digital Medicine(2025)10.1038/s41746-025-01978-4

N/A

0DataRank · unranked

2 citations

Jonathan Martinez, Bahar Tercan, Heikki Kuusanmäki, Frank Emmert‐Streib, Jerome G. Chandraseelan +10 more